bupropion / Generic mfg. - LARVOL DELTA

Inpatient Tobacco Cessation Counseling and Treatment: A Survey of U.S.-Based Cardiologists. (PubMed, JACC Adv) - "Although tobacco cessation is critical posthospitalization, most hospitals do not have tobacco cessation teams, and most cardiologists do not assist their patients in quit attempts. Although improving knowledge among cardiologists is important, policy changes to incentivize hospital-wide adoption of such programs is crucial to increase availability."

Journal • Cardiovascular • Tobacco Cessation

Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study (ASH 2025) - "Adult patients with multiple myeloma since 2010 and prescribed antidepressants (sertraline, escitalopram, citalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, trazodone, mirtazapine, or bupropion) were identified using ICD-10 diagnostic and RxNorm codes. While some associations were modest in magnitude, the consistent pattern of increased risk suggests that pre-existing depression and its treatment may identify a more vulnerable subgroup of multiple myeloma patients. Further prospective studies are needed to clarify underlying mechanisms and to evaluate the potential impact of early psychiatric intervention."

Clinical data • Retrospective data • Chronic Kidney Disease • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Major Depressive Disorder • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Renal Disease

Antidepressant agent use and risk of bleeding in patients with cancer: Results from the vienna CAT-bled study (ASH 2025) - "Antidepressants were used in 218 patients (18.8%) at inclusion, with selective-serotonin re-uptake inhibitors (SSRIs) in 91 (7.8%), serotonin antagonist-re-uptake inhibitors (SARIs) in 75 (6.5%), other agents (mirtazapine, amitriptyline or bupropion) in 68 (5.9%), and serotonin-noradrenaline re-uptake inhibitors (SNRIs) in 13 (1.1%) patients. Among different types of antidepressants, the highest bleeding-risk was observed among SSRI users. Concomitant use of antidepressants and antiplatelet agents was associated with a particularly high bleeding risk, warranting further investigations."

Clinical • Gastrointestinal Disorder • Oncology • Thrombosis

Bupropion for Treatment of Depression and Narcolepsy in a Postpartum Patient. (PubMed, Prim Care Companion CNS Disord) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Narcolepsy • Psychiatry • Sleep Disorder

Bupropion-induced tinnitus after dose escalation: a rare and reversible adverse effect - a case report. (PubMed, Ann Med Surg (Lond)) - "The rarity and reversibility highlight the need for vigilance, patient education during dose escalation, and timely dose adjustment or discontinuation. Limitations include the single-case design and possible confounders such as comorbid anxiety."

Adverse events • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Otorhinolaryngology • Psychiatry • Tobacco Cessation

Mediation Effects of Biobehavioral Factors in a Trial of Pharmacotherapy and Intensive Cessation Counseling for People with HIV Who Smoke Cigarettes in Nairobi, Kenya. (PubMed, AIDS Behav) - P3 | "None of the putative mediators demonstrated a significant mediation effect of bupropion on quitting. These results indicate that self-efficacy was one mechanism through which PSF counseling, but not bupropion, increased smoking abstinence among PWH who smoked cigarettes in Nairobi, Kenya.Trial Registration: NCT02460900."

Journal • Human Immunodeficiency Virus • Infectious Disease

The efficacy and safety of antidepressants as alternative treatment of attention-deficit/hyperactivity disorder in pediatric populations. (PubMed, Ment Health Clin) - "Beyond behavioral therapy approaches, methylphenidate and amphetamine stimulant agents are recommended as first-line pharmaceutical treatments for ADHD...Particular focus on selective serotonin reuptake inhibitors, SNRIs, tricyclic antidepressants, and bupropion was demonstrated in the literature. More research needs to be conducted to fully explore the effects and efficacy of antidepressants compared with first-line medications for ADHD. In addition, data supporting long-term effects and efficacy for antidepressants in ADHD are not yet established."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Pediatrics • Psychiatry

Pharmacological interventions to manage cardiometabolic outcomes in adults with severe mental illness: umbrella review. (PubMed, Br J Psychiatry) - "Pharmacological interventions can improve cardiometabolic outcomes in adults with SMI when non-pharmacological interventions are either insufficient alone, impractical or unacceptable. However, licensed treatments have been reviewed in relatively low numbers. Improving cardiometabolic outcomes is a key area in psychiatry, and the results of this review will be important in shaping future guidance."

Journal • CNS Disorders • Dyslipidemia • Psychiatry • Tobacco Cessation

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: SpringWorks Therapeutics, Inc.

New P1 trial

Evaluation of a Second-line Treatment in Female Adolescents With SSRI-nonresponsive Major Depression: A Real-world Data Analysis on Bupropion Versus Duloxetine. (PubMed, J Psychiatr Pract) - "This study is distinct in its focus on female adolescents with MDD, applying a triple-blind design and utilizing both standardized (MADRS) and personalized (GAS-D) outcome measures. By including an analysis of suicide attempt rates, it offers important clinical insights into the comparative effectiveness and safety of bupropion and duloxetine in a particularly vulnerable population."

Clinical • Journal • Real-world evidence • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Suicidal Ideation

CONCORD: Combination of Novel Therapies for CKD Comorbid Depression (clinicaltrials.gov) - P2 | N=201 | Recruiting | Sponsor: Stony Brook University | Trial completion date: Apr 2026 ➔ Apr 2027 | Trial primary completion date: Apr 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Chronic Kidney Disease • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Nephrology • Psychiatry • Renal Disease

SMARTTT: A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (clinicaltrials.gov) - P4 | N=323 | Completed | Sponsor: Yale University | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • Nicotine Addiction • Tobacco Addiction • Tobacco Cessation

Utilizing Pharmacogenetic Results to Optimize Medication Management in Hospice Care: A Pilot Study. (PubMed, J Pers Med) - "Three patients underwent medication changes based on PGx guidance, including switching from citalopram to bupropion and adding morphine to tramadol therapy, which improved symptom control. While not yet routinely implemented in hospice settings, this pilot study suggests PGx-guided prescribing can support personalized medication decisions and enhance emotional and physical comfort in end-of-life care when test results are available."

Biomarker • Journal • Pain • Palliative care

FARFOOD: a database of potential interactions between food compounds and drugs. (PubMed, BioData Min) - No abstract available

Journal

Characterization of Tobacco Cessation Services, Pharmacotherapies, and Policies at Adolescent-serving Substance Use Treatment Facilities in 2023. (PubMed, J Addict Med) - "While most adolescent-only substance use treatment facilities offered tobacco cessation education or counseling and restricted tobacco use at their sites, they were less likely than adult/adolescent facilities to offer pharmacotherapy for tobacco cessation. This reflects a missed opportunity to offer robust options to treat tobacco use among adolescents with substance use disorders."

Journal • Tobacco Cessation

A Drug-Drug Interaction Study of EPX-100 (Clemizole Hydrochloride) With Clinical Probe Substrates for Selected CYP Enzymes (AES 2025) - P3 | "Each part was designed as a 2-period fixed sequence, with Parts 1 and 2 involving administration of a single oral 80-mg dose of EPX-100 on Day 1 (Period 1), followed in Period 2 by either 200-mg oral itraconazole twice daily for 1 day followed by 200-mg oral itraconazole once daily for 4 days (Part 1), or 100-mg oral phenytoin 3 times daily for 14 days (Part 2)...During Period 2, 80-mg twice-daily doses of EPX-100 were administered for 18 days with a single oral dose of 40-mg omeprazole, 2-mg midazolam, or 100-mg bupropion on Days 12, 14, and 15, respectively... The drug-drug interaction profile with EPX-100 has been evaluated, and final results will be presented. EPX-100 was generally safe and well tolerated in this study of healthy participants. Findings from this study will inform other studies of EPX‑100, including the currently enrolling ARGUS study for DS (NCT04462770) and the LIGHTHOUSE study for LGS (NCT05066217)."

Clinical • CNS Disorders • Epilepsy • CYP2C19 • CYP3A4

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

New P1 trial • Breast Cancer • Oncology • Solid Tumor

Comparative BMI-z Changes With Initiation and Adherence to Antidepressant Medications Among Youth. (PubMed, J Am Acad Child Adolesc Psychiatry) - "Among youth, initiation and adherence to bupropion was not associated with 12-month BMI-z change, though four other most-common antidepressants were associated with small increases in BMI-z over this time. Clinicians should consider these differences when prescribing antidepressants to youth, alongside FDA approvals, clinical guidelines, and evidence of safety and efficacy."

Journal

Canine duodenal organoids as a functional platform for intestinal CYP regulation and drug metabolism studies. (PubMed, Drug Metab Dispos) - "CYP3A98 and CYP2B11 gene expression was assessed by quantitative reverse transcription polymerase chain reaction, while enzyme function was evaluated using midazolam (CYP3A98) and bupropion (CYP2B11) hydroxylation assays. To assess P450 induction, organoids were treated with rifampicin (a pregnane X receptor [PXR] selective inducer) and phenobarbital (a constitutive androstane receptor [CAR] inducer)...SIGNIFICANCE STATEMENT: A physiologic canine intestinal in vitro model for drug development is lacking in veterinary medicine. The canine differentiated duodenal organoids used in this study expressed CYP3A98 and CYP2B11 enzymes and may provide a physiological platform for studying drug metabolism and drug-drug interactions during the development of veterinary pharmaceuticals."

Journal

Antidepressant-like and neuroprotective effects of pine needle extracts: evidence from behavioral, transcriptomic, and biochemical studies. (PubMed, EXCLI J) - "Following seven days of oral administration of PN, the tail suspension test demonstrated a significant reduction in immobility time in PN-treated mice compared to LPS controls, surpassing the effect of the standard antidepressant bupropion...See also the graphical abstract(Fig. 1)."

Journal • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry • IL1B • TNFA

Cognitive changes in older adults receiving pharmacotherapy for treatment-resistant depression: a secondary analysis of the OPTIMUM randomised controlled trial. (PubMed, Lancet Healthy Longev) - P4 | "Overall, global cognitive functioning did not differ between treatments. Aripiprazole augmentation and switch to nortriptyline might have some modest advantages in inhibitory control compared with bupropion or lithium augmentation."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Cannabidiol Transiently Reduces Nicotine Vapor Self-Administration in Mice (Neuroscience 2025) - "First-line cessation aids, including nicotine replacement therapy, varenicline, and bupropion, show limited long-term efficacy. During 21- day chronic administration, we observe a transient decrease in nicotine self-administration during the first week, but not the second or third weeks of testing. Together the data help to elucidate the behavioral effects of CBD administration on nicotine intake behaviors and the potential of CBD as a nicotine cessation therapeutic."

Preclinical • CNS Disorders • Nicotine Addiction • Psychiatry

Evaluation of Antidepressants for Attenuation of Effort-Related Motivational Dysfunction in Male and Female Rats: the Importance of Dopamine (Neuroscience 2025) - "In contrast, drugs acting on dopamine (DA) and norepinephrine (NE) transporters (DAT and NET respectively), such as bupropion, are reported to be more effective at treating motivational dysfunction...Microdialysis methods are being used to assess potential differences in the neurochemical effects of these MAT inhibitors in male and female rats, to compare with the behavioral results. In summary, facilitation of DA transmission is critical for the attenuation of effort-based motivation dysfunctions, but sex differences must be taken into account."

Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Perinatal interference with the serotonergic system affects VTA function in the adult and leads to motivation deficits (Neuroscience 2025) - "We hypothesize that early-life exposure to altered serotonin levels causes alterations in the dopaminergic system and long-lasting dopamine-dependent behavioral changes.To test whether changes in serotonergic levels in early-life affect dopamine dependent behaviors we administered the SSRI Fluoxetine (FLX) to mice, from postnatal day (P)2 to P11 (PN-FLX). This deficit was successfully ameliorated by administering bupropion in PN-FLX mice, while the administration of FLX did not yield similar results. Currently we are testing whether directly stimulating the dopaminergic system improves the deficits in behavioral phenotypes caused by early-life exposure to SSRIs."

Clinical • CNS Disorders • Mood Disorders • Psychiatry

High throughput assessment of barrier function using human ipsc-derived brain microvascular endothelial cells (Neuroscience 2025) - "bupropion, mannitol, prazosin, VEGF, and verapamil. CONCLUSIONS Characterization of and testing with the individual cellular components that make up the BBB provides added insight to the functional aspects of this complex system. Human iPSC-derived BMEC offer a robust and reliable source of cells to interrogate the multiple properties of this specialized cell type."

CNS Disorders